Client News
Filter by:
- Sep 22 2022 NeuBase to Participate at Chardan’s 6th Annual Genetic Medicines Conference
- Sep 21 2022 Adamis Provides Update on the Phase 2/3 Trial of Tempol in COVID-19 Positive High-Risk Subjects
- Sep 14 2022 NetCents Technology Provides Update on the Status of the Audit of Its 2020 and 2021 Financial Statements
- Sep 12 2022 Adamis Provides an Enrollment Update on the Phase 2/3 Study of Tempol in COVID-19 Positive High-Risk Subjects
- Aug 11 2022 NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
- Jan 6 2022 Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities
- Jan 4 2022 Arch Therapeutics Announces Appointment of Guy Fish to the Board
- Dec 17 2021 OncoSec Announces Changes to its Board of Directors
- Dec 14 2021 INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
- Dec 13 2021 Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System